Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17066
Country/Region: Uganda
Year: 2017
Main Partner: World Vision
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $1,061,113 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $38,208
Care: TB/HIV (HVTB) $9,172
Care: Pediatric Care and Support (PDCS) $1,564
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $136,826
Testing: HIV Testing and Counseling (HVCT) $104,278
Sexual Prevention: Other Sexual Prevention (HVOP) $680,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $12,767
Treatment: Adult Treatment (HTXS) $77,119
Treatment: Pediatric Treatment (PDTX) $1,179
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2018 15
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2018 31
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2018 111
GEND_GBV Number of people receiving post-GBV care 2018 157
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 29,910
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2018 1
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2018 8
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2018 5
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2018 45
HTS_TST Service Delivery Point (Community) Index Mod: 25-49, Female, Negative 2018 26
HTS_TST Service Delivery Point (Community) Index Mod: 25-49, Male, Negative 2018 95
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Female, Negative 2018 1
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Male, Negative 2018 2
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative 2018 50
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative 2018 149
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative 2018 100
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative 2018 248
HTS_TST Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative 2018 87
HTS_TST Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative 2018 248
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative 2018 50
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative 2018 50
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2018 2,376
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2018 2,771
HTS_TST Service Delivery Point (Facility) ANC: 25-49, Negative 2018 2,376
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2018 396
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2018 54
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2018 10
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2018 43
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2018 32
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2018 247
HTS_TST Service Delivery Point (Facility) Index: 25-49, Female, Negative 2018 107
HTS_TST Service Delivery Point (Facility) Index: 25-49, Male, Negative 2018 508
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2018 12
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2018 13
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2018 105
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2018 7
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2018 99
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2018 57
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2018 721
HTS_TST Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative 2018 98
HTS_TST Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative 2018 1,410
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2018 7
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2018 7
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2018 106
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2018 73
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2018 353
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2018 313
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2018 2,197
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative 2018 1,047
HTS_TST Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative 2018 4,706
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2018 96
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2018 109
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2018 54
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2018 1
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2018 7
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2018 2
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2018 37
HTS_TST Service Delivery Point (Facility) TB: 25-49, Female, Negative 2018 11
HTS_TST Service Delivery Point (Facility) TB: 25-49, Male, Negative 2018 66
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2018 1
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2018 1
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2018 1,888
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2018 2,202
HTS_TST Service Delivery Point (Facility) VMMC: 25-49, Negative 2018 1,888
HTS_TST Service Delivery Point (Facility) VMMC: 50+, Negative 2018 316
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2018 2
HTS_TST Sum of Test Result disaggregates 2018 1,813
HTS_TST_POS By Test Result: Positive 2018 1,813
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Male, Positive 2018 4
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2018 3
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2018 26
HTS_TST_POS Service Delivery Point (Community) Index Mod: 25-49, Female, Positive 2018 12
HTS_TST_POS Service Delivery Point (Community) Index Mod: 25-49, Male, Positive 2018 52
HTS_TST_POS Service Delivery Point (Community) Index Mod: 50+, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Community) Index Mod: 50+, Male, Positive 2018 1
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive 2018 4
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive 2018 16
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive 2018 11
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive 2018 30
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive 2018 13
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive 2018 29
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive 2018 3
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2018 88
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2018 104
HTS_TST_POS Service Delivery Point (Facility) ANC: 25-49, Positive 2018 88
HTS_TST_POS Service Delivery Point (Facility) ANC: 50+, Positive 2018 15
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2018 25
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2018 19
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2018 139
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Female, Positive 2018 61
HTS_TST_POS Service Delivery Point (Facility) Index: 25-49, Male, Positive 2018 284
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2018 8
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2018 2
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2018 4
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2018 31
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive 2018 61
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2018 22
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2018 15
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2018 129
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive 2018 51
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive 2018 263
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2018 7
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2018 3
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2018 1
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2018 14
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Female, Positive 2018 6
HTS_TST_POS Service Delivery Point (Facility) TB: 25-49, Male, Positive 2018 27
HTS_TST_POS Service Delivery Point (Facility) VMMC: 15-19, Positive 2018 14
HTS_TST_POS Service Delivery Point (Facility) VMMC: 20-24, Positive 2018 40
HTS_TST_POS Service Delivery Point (Facility) VMMC: 25-49, Positive 2018 46
HTS_TST_POS Service Delivery Point (Facility) VMMC: 50+, Positive 2018 4
PMTCT_ART Already on ART at beginning of current pregnancy 2018 11
PMTCT_ART Already on ART at beginning of current pregnancy 2018 117
PMTCT_ART New on ART 2018 9
PMTCT_ART New on ART 2018 96
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 20
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2018 213
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 229
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 2,881
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 174
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2018 17
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 6
PMTCT_EID Number of infants with a negative virological test result between 2 and 12 months of birth 2018 53
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 11
PMTCT_EID Number of infants with a negative virological test result within 2 months of birth 2018 115
PMTCT_EID Number of infants with a positive virological test result between 2 and 12 months of birth 2018 1
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2018 5
PMTCT_STAT By Age (Numerator): : 15-19 2018 43
PMTCT_STAT By Age (Numerator): 10-14 2018 3
PMTCT_STAT By Age (Numerator): 10-14 2018 28
PMTCT_STAT By Age (Numerator): 15-19 2018 548
PMTCT_STAT By Age (Numerator): 20-24 2018 43
PMTCT_STAT By Age (Numerator): 20-24 2018 548
PMTCT_STAT By Age (Numerator): 25-49 2018 140
PMTCT_STAT By Age (Numerator): 25-49 2018 1,757
PMTCT_STAT By known positives: 15-19 2018 3
PMTCT_STAT By known positives: 20-24 2018 5
PMTCT_STAT By known positives: 25-49 2018 5
PMTCT_STAT By new negatives: 10-14 2018 3
PMTCT_STAT By new negatives: 15-19 2018 39
PMTCT_STAT By new negatives: 20-24 2018 35
PMTCT_STAT By new negatives: 25-49 2018 132
PMTCT_STAT By new positives: 15-19 2018 1
PMTCT_STAT By new positives: 20-24 2018 3
PMTCT_STAT By new positives: 25-49 2018 3
PMTCT_STAT By Number of known positives: 10-14 2018 1
PMTCT_STAT By Number of known positives: 15-19 2018 25
PMTCT_STAT By Number of known positives: 20-24 2018 45
PMTCT_STAT By Number of known positives: 25-49 2018 62
PMTCT_STAT By Number of new negative: 10-14 2018 26
PMTCT_STAT By Number of new negative: 15-19 2018 506
PMTCT_STAT By Number of new negative: 20-24 2018 472
PMTCT_STAT By Number of new negative: 25-49 2018 1,652
PMTCT_STAT By Number of new positives: 10-14 2018 1
PMTCT_STAT By Number of new positives: 15-19 2018 17
PMTCT_STAT By Number of new positives: 20-24 2018 31
PMTCT_STAT By Number of new positives: 25-49 2018 43
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 229
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2018 2,881
PMTCT_STAT_den By Age (Denominator): <15-19 2018 548
PMTCT_STAT_den By Age (Denominator): 10-14 2018 3
PMTCT_STAT_den By Age (Denominator): 10-14 2018 28
PMTCT_STAT_den By Age (Denominator): 15-19 2018 43
PMTCT_STAT_den By Age (Denominator): 20-24 2018 43
PMTCT_STAT_den By Age (Denominator): 20-24 2018 548
PMTCT_STAT_den By Age (Denominator): 25-49 2018 140
PMTCT_STAT_den By Age (Denominator): 25-49 2018 1,757
PP_PREV Age/sex: 10-14 Female 2018 6,310
PP_PREV Age/sex: 10-14 Male 2018 5,199
PP_PREV Age/sex: 15-19 Female 2018 3,387
PP_PREV Age/sex: 15-19 Male 2018 2,698
PP_PREV Age/sex: 20-24 Female 2018 2,411
PP_PREV Age/sex: 20-24 Male 2018 2,489
PP_PREV Age/sex: 25-49 Female 2018 7,467
PP_PREV Age/sex: 25-49 Male 2018 8,661
PP_PREV Age/sex: 50+ Female 2018 617
PP_PREV Age/sex: 50+ Male 2018 765
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 40,004
PP_PREV Sum of Age/Sex disaggregates 2018 40,004
PrEP_NEW Female 15-19 2018 56
PrEP_NEW Female 20-24 2018 56
PrEP_NEW Female 25-49 2018 56
PrEP_NEW Female 50+ 2018 58
PrEP_NEW FSW 2018 41
PrEP_NEW Male 15-19 2018 56
PrEP_NEW Male 20-24 2018 56
PrEP_NEW Male 25-49 2018 56
PrEP_NEW Male 50+ 2018 56
PrEP_NEW MSM 2018 2
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2018 450
PrEP_NEW TG 2018 1
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 5
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2018 14
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2018 21
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2018 19
TB_ART_den Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 5
TB_ART_den Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 1
TB_ART_den Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period) 2018 15
TB_PREV By Age/Sex (Numerator): 15+, Female 2018 11
TB_PREV By Age/Sex (Numerator): 15+, Male 2018 128
TB_PREV By Therapy type (Numerator): 6-12 Month IPT 2018 139
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2018 139
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2018 280
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2018 25
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2018 255
TB_PREV_den By Therapy type (Denominator): 6-12 Month IPT 2018 280
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 1
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 13
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 1
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2018 24
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2018 39
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2018 39
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 1
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 13
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 1
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2018 24
TX_CURR Age/Sex: <1 2018 14
TX_CURR Age/Sex: <1-9 2018 14
TX_CURR Age/Sex: 10-14 Female 2018 39
TX_CURR Age/Sex: 10-14 Male 2018 39
TX_CURR Age/Sex: 15-19 Female 2018 97
TX_CURR Age/Sex: 15-19 Male 2018 26
TX_CURR Age/Sex: 20-24 Female 2018 291
TX_CURR Age/Sex: 20-24 Male 2018 160
TX_CURR Age/Sex: 25-49 Female 2018 490
TX_CURR Age/Sex: 25-49 Male 2018 270
TX_CURR Age/Sex: 50+ Female 2018 97
TX_CURR Age/Sex: 50+ Male 2018 3
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 1,540
TX_CURR Sum of age/sex disaggregates 2018 123
TX_NEW By Age/Sex: 15-19 Female 2018 2
TX_NEW By Age/Sex: 15-19 Male 2018 15
TX_NEW By Age/Sex: 20-24 Female 2018 8
TX_NEW By Age/Sex: 20-24 Male 2018 93
TX_NEW By Age/Sex: 25-49 Female 2018 15
TX_NEW By Age/Sex: 25-49 Male 2018 172
TX_NEW By Age/Sex: 50+ Female 2018 2
TX_NEW By Age/Sex: 50+ Male 2018 2
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 309
TX_NEW Sum of Age/Sex disaggregates 2018 309
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 1,388
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 1,249
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 45
TX_PVLS Numerator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 45
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 793
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 366
TX_PVLS Numerator: Indication: Routine 2018 1,249
TX_PVLS Numerator: Preg/BF by Indication: Breastfeeding Routine 2018 6
TX_PVLS Numerator: Preg/BF by Indication: Pregnant Routine 2018 125
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2018 52
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2018 52
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 876
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 408
TX_PVLS_den Denominator: Indication: Routine 2018 1,388
TX_PVLS_den Denominator: Preg/BF by Indication: Breastfeeding Routine 2018 6
TX_PVLS_den Denominator: Preg/BF by Indication: Pregnant Routine 2018 138
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 9
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 9
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 133
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 73
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 224
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 250
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 9
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 9
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 147
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 85
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2018 1,540
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2018 31
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2018 21
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2018 10
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2018 55
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2018 55
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2018 978
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2018 452
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2018 87
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert) 2018 11
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2018 26
TX_TB_den Denominator: By Screen Result: Negative 2018 1,416
TX_TB_den Denominator: By Screen Result: Positive 2018 124
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2018 124
VMMC_CIRC By Age: 10-14 2018 1,399
VMMC_CIRC By Age: 15-19 2018 2,520
VMMC_CIRC By Age: 20-24 2018 3,358
VMMC_CIRC By Age: 25-29 2018 5,316
VMMC_CIRC By Age: 30-49 2018 840
VMMC_CIRC By Age: 50+ 2018 561
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2018 13,994
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2018 13,994
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2018 7,838
Cross Cutting Budget Categories and Known Amounts Total: $490,000
Gender: Gender Based Violence (GBV) $180,000
GBV Prevention
Capacity building
Monitoring and Evaluation
Post GBV Care
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $100,000
Changing harmful gender norms and promoting positive gender norms
Implementation
Capacity building
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Implementation
Capacity building
Monitoring and Evaluation
Key Populations: Sex Workers $150,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Water $30,000
Condoms: Policy, Tools, and Services $30,000